We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » SCOTUS Spin-Off: Novartis Seeks Preemption for Brand Drugmakers
SCOTUS Spin-Off: Novartis Seeks Preemption for Brand Drugmakers
July 12, 2013
The Novartis v. Fussman liability case pending before the Supreme Court should extend to brand drugmakers similar preemptive protection from state court-ordered punitive damages as those now afforded generic drug companies, a brief filed by the Washington Legal Foundation (WLF) argues.